PAP
BMRN icon

Persistent Asset Partners’s BioMarin Pharmaceuticals BMRN Stock Holding History

Persistent Asset Partners’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.57M Buy
79,933
+42,461
+113% +$2.33M 1.36% 14
2026
Q1 		$2.12M Sell
37,472
-1,663
-4% -$97K 0.79% 29
2025
Q4 		$2.33M Sell
39,135
-9,731
-20% -$530K 1.04% 15
2025
Q3 		$2.65M Buy
48,866
+4,602
+10% +$263K 1.82% 10
2025
Q2 		$2.43M Buy
44,264
+32,181
+266% +$1.9M 1.8% 14
2025
Q1 		$854K Sell
12,083
-14,773
-55% -$994K 0.72% 40
2024
Q4 		$1.7M Buy
+26,856
New +$1.8M 1.41% 17

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Persistent Asset Partners's BMRN Position: Q2 2026 in Review

Persistent Asset Partners increased its BioMarin Pharmaceuticals (BMRN) stake by 113% in Q2 2026, buying an estimated $2.33M and bringing the position to 79,933 shares worth $4.57M. The position accounts for 1.36% of the portfolio, ranked #14.

Persistent Asset Partners first reported a position in BMRN in Q4 2024 and has held it in 7 quarters since. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • Persistent Asset Partners held 79,933 shares of BioMarin Pharmaceuticals worth $4.57M as of Q2 2026.
  • Persistent Asset Partners bought 42,461 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $2.33M.
  • BioMarin Pharmaceuticals made up 1.36% of Persistent Asset Partners's portfolio in Q2 2026, its #14 holding.
  • Persistent Asset Partners first reported a position in BioMarin Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
  • 565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Persistent Asset Partners's 13F filing for Q2 2026, filed 7 Aug 2026.